Recent 8-K filings for GRI

• June 18, 2026, 4:50 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  GRI Bio receives FDA Orphan Drug Designation for GRI-0621 in IPF

  FDA granted Orphan Drug Designation to GRI-0621 for idiopathic pulmonary fibrosis.

• May 14, 2026, 8:36 AM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF

  Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.

• February 4, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027

  Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.

• January 30, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  GRI Bio expands ATM equity offering capacity from $10M to $60M via H.C. Wainwright amendment

  Amendment to At The Market Offering Agreement increases aggregate offering price to $60 million.

• January 28, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF

  Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.

• January 21, 2026, 6:59 PM ET other material materiality 0.45 neutral item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes

  GRI Bio announces 1-for-28 reverse stock split effective Jan 23, 2026 to regain Nasdaq compliance

  Stockholders approved reverse split at January 15, 2026 special meeting.

• January 16, 2026, 6:59 PM ET regulatory materiality 0.60 positive item 3.01 ◈ Listing & Compliance Notices

  GRI Bio conditionally regains Nasdaq equity compliance after prior deficiency

  Nasdaq Staff notified GRI Bio on Jan 15, 2026 that it conditionally regained compliance with the Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).

• January 15, 2026, 6:59 PM ET regulatory materiality 0.60 negative item 5.07item 8.01

  GRI Bio shareholders approve reverse stock split; company addresses Nasdaq equity deficiency with $8M offering

  Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.

• January 9, 2026, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  GRI Bio increases ATM offering capacity to $7.38M, waives Dec 2025 SPA restrictions

  Increased ATM capacity by up to $7.38M in common stock; $6.17M already sold under the program.

• January 8, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF

  Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.

• December 12, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  GRI Bio launches $6.7M public offering of common stock and warrants

  Offering comprises 2.6M shares, 8.1M pre-funded warrants ($0.0001/share), and 10.7M Series F warrants ($0.75/share) at $0.75 per unit.

• December 12, 2025, 6:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  GRI Bio closes $8.0M public offering of common stock and Series F warrants

  Offering of 10,666,667 shares (or equivalents) plus Series F warrants to buy same number at $0.75/share.

• December 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF

  Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.

• December 8, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01

  GRI Bio reports positive Phase 2a data for GRI-0621 in IPF; primary endpoint met

  Phase 2a trial (35 IPF subjects, 2:1 randomization) met primary safety endpoint; GRI-0621 well tolerated over 12 weeks with no treatment-related SAEs.

• December 2, 2025, 6:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  GRI BIO receives Nasdaq delisting notice for stockholders' equity deficiency

  Nasdaq notified GRI BIO of non-compliance with minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).

• August 20, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  GRI Bio files corporate presentation with no material new disclosures

  Furnished a corporate presentation dated August 20, 2025 under Regulation FD.

• August 13, 2025, 7:59 PM ET other materiality 0.30 neutral item 5.02item 5.07item 9.01

  Shareholders approve 400,000-share increase to GRI Bio's 2018 Equity Incentive Plan

  Shareholders voted 48,362 to 17,889 (179 abstain) to approve the amendment; broker non-votes: 1,023,943.

• July 31, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  GRI Bio reports positive interim biomarker data from Phase 2a IPF study; IDMC recommends continuation

  6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.

• June 26, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation

  IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.

• May 23, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  GRI Bio increases ATM offering capacity by $1.76M after selling $4.55M previously

  Filed prospectus supplement to increase maximum shares issuable under ATM to $1,758,934.

• May 15, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025

  Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.

• May 5, 2025, 7:59 PM ET other material materiality 0.55 negative item 8.01item 9.01

  GRI Bio increases ATM offering capacity by up to $1.67M, on top of $3.6M already sold

  Prospectus supplement filed to increase ATM issuance by up to $1.67M, on top of $3.6M previously sold.

• April 16, 2025, 7:59 PM ET other material materiality 0.65 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  GRI Bio dismisses auditor Sadler Gibb, appoints WithumSmith+Brown as new independent accountant.

  Audit Committee dismissed Sadler Gibb on April 11, 2025; no disagreements on accounting principles or practices.

• April 2, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01

  GRI Bio prices $5M public offering of shares and warrants; net proceeds ~$4.2M

  Priced public offering of 1,388,888 units at $3.60 each (share or pre-funded warrant plus Series E-1, E-2, E-3 warrants).

• March 17, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025

  Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.

• March 11, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 3.01item 8.01item 9.01 ◈ Listing & Compliance Notices

  GRI Bio regains compliance with Nasdaq minimum bid price rule

  Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).

• February 19, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes

  GRI Bio announces 1-for-17 reverse stock split effective Feb 21, 2025

  Reverse split at 1:17 ratio, effective 4:01 p.m. ET on Feb 21, 2025; post-split trading begins Feb 24, 2025 on Nasdaq under symbol GRI.

• February 11, 2025, 6:59 PM ET other material materiality 0.45 neutral item 5.07

  GRI Bio shareholders authorize reverse stock split at ratio of 1:2 to 1:23

  Special meeting held Feb 11, 2025; quorum of 4,640,469 shares (51.94%) present.

• December 20, 2024, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  GRI Bio increases at-the-market offering capacity to $322,468 after $3.6M already sold

  On December 20, 2024, GRI Bio filed a prospectus supplement to increase shares issuable under its ATM agreement with H.C. Wainwright to up to $322,468.

• November 14, 2024, 6:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025

  Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.

• October 24, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025

  Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.

• October 22, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 3.03item 8.01item 9.01

  GRI Bio amends warrants; raises $0.8M by reducing exercise price to $1.00

  Entered repricing agreements for 762,236 Series B warrants; holders exercise at $1.00/share (down from $14.30) for gross proceeds of $762,236.

• September 11, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 5.07item 3.01

  GRI Bio receives Nasdaq deficiency notice for bid price below $1; 180-day cure period until March 10, 2025

  Received Nasdaq letter on Sept 10, 2024 for failing minimum bid price of $1.00 over 30 consecutive business days.

• September 11, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 5.07

  GRI Bio receives Nasdaq deficiency notice for minimum bid price non-compliance

  Received Nasdaq letter on Sept 10, 2024; closing bid price below $1.00 for 30 consecutive business days.

• September 6, 2024, 7:59 PM ET other material materiality 0.15 negative item 5.07

  GRI Bio shareholders reject equity plan increase by 600K shares; director David Baker elected

  David Baker elected Class I director with 61,134 for vs 40,091 against (155 abstain).

• August 23, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  GRI Bio adjourns 2024 annual meeting to Sept 6 to solicit more proxies for outstanding proposals

  Only 34.58% of shares present (256,566 of 741,914); quorum was barely met at one-third threshold.

• August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track

  Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).

• July 26, 2024, 7:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  GRI Bio increases ATM offering capacity to $2.64M, reports $961K already sold

  Maximum aggregate gross proceeds from ATM offering raised to $2,644,609 via prospectus supplement filed July 26, 2024.

• July 19, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01item 9.01

  GRI Bio increases ATM offering capacity by up to $1.04M, excluding prior $0.96M sales

  Increased maximum aggregate sales price of shares under ATM agreement with H.C. Wainwright to $1,038,886, excluding $961,272 already sold.

• July 8, 2024, 7:59 PM ET regulatory materiality 0.60 positive item 3.01item 8.01item 9.01

  GRI Bio regains compliance with Nasdaq continued listing standards

  Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).

• June 27, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  GRI Bio prices $4.0M public offering of shares and warrants at $1.83/unit

  Offering of 2,185,793 shares (or equivalents) plus Series C-1 and C-2 warrants at $1.83 per unit.

• June 18, 2024, 7:59 PM ET other material materiality 0.60 negative item 5.02item 9.01

  GRI Bio CMO Albert Agro reduced to 70 hrs/month, salary cut to $100k

  CMO Albert Agro's base salary reduced from $325,000 to $100,000 annually.

• June 14, 2024, 7:59 PM ET other material materiality 0.60 negative item 3.03item 5.03item 8.01item 9.01

  GRI Bio announces 1-for-13 reverse stock split to regain Nasdaq compliance

  Reverse split at 1-for-13 effective 4:01 p.m. ET June 17, 2024; split-adjusted trading starts June 18, 2024.

• June 7, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.07

  GRI Bio stockholders approve reverse stock split in range of 1:2 to 1:15

  Proposal 1 approved: 1,417,003 votes for, 310,490 against, 120 abstained.

• May 22, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  GRI Bio receives Nasdaq delisting determination; plans to appeal by May 28, 2024

  Received Nasdaq Staff determination letter on May 21, 2024, for non-compliance with stockholders' equity rule (Rule 5550(b)) after initial 180-day cure period ended May 20, 2024.

• May 20, 2024, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01

  GRI Bio enters into ATM equity offering agreement with H.C. Wainwright for up to $961,579

  Company may sell up to $961,579 of common stock through H.C. Wainwright as sales agent.

• May 13, 2024, 7:59 PM ET other material materiality 0.60 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024

  Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.

• April 1, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering

  Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).

• February 2, 2024, 6:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01 ◈ Material Agreements ×2

  GRI Bio prices $5.5M public offering of common stock and warrants at $1.10/unit

  Priced offering of 5,000,000 shares (or pre-funded warrants) at $1.10 per share, raising $5.5M gross proceeds.

• January 30, 2024, 6:59 PM ET other material materiality 0.55 neutral item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes

  GRI Bio implements 1-for-7 reverse stock split to regain Nasdaq compliance

  Effective 4:01 p.m. ET Jan 29, 2024; post-split trading begins Jan 30 under symbol GRI.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

12 positive 12 negative 26 neutral

source · GRI on sec.gov